Zenas BioPharma, Inc.

NASDAQ:ZBIO

Biotechnology

Healthcare
$26.42 +3.46%

+$0.64 today

Market cap
$1.79B
Beta
-0.69
P/E (TTM)
-2.5
EPS (TTM)
-$7.64
52W Low $8.91High $44.60

Volume 0.48M

Average 0.71M

ZBIO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Zenas BioPharma, Inc.NASDAQ: ZBIO

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 55.62M shares rose 33.1% year over year, ahead of the +13.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 19.6% from the prior quarter. Over 3 fiscal years it compounded at +5.3% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +33.1% holds above the trailing-twelve-month pace of +13.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
55.62M+19.6% QoQ
Last fiscal yearDec 2025
44.73M+7.0% YoY
LTMMar 2026
46.54M+13.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.1%——
1 year+7.0%——
3-year CAGR+5.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
44.73M USD
Year-over-year change
+7.0%
3-year CAGR
+5.3%

Weighted Avg Shares vs competitors

How ZBIO compares with its peers on the latest reported figures

  • ZBIO's LTM Mar 2026 weighted avg shares of 46.54M shares is the 6th highest of the 8 companies compared; the peer median is 59.14M shares.
  • Its year-over-year change of +13.7% is the 4th highest of 7, against a peer median of +12.6%.
  • Over three fiscal years its annual growth of +5.3% compares with a peer median of +18.7%.
ZBIO Competitors Peer median
Weighted Avg Shares for ZBIO and competitors
Company Period LTM YoY 3-year CAGR
IMVTImmunovant, Inc.LTM Sep 2026199.36M +24.0%+14.0%
ANNXAnnexon, Inc.LTM Mar 2026161.69M +14.3%+41.6%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
TLSATiziana Life Sciences LtdFY202559.14M +10.9%+5.2%
UPBUpstream Bio, Inc.LTM Mar 202654.07M +4.2%+14.0%
ZBIOZenas BioPharma, Inc.LTM Mar 202646.54M +13.7%+5.3%
QTTBQ32 Bio Inc.LTM Mar 202612.77M +5.5%+56.8%
TRAXFirst Tracks Biotherapeutics IncFY20250 ——
Peer median (excluding ZBIO) 59.14M+12.6%+18.7%

Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue050M5M10M
Cost of Revenue61.69M0139.14M0
Gross Profit(61.69M)50M(134.14M)10M
Gross Margin—100.0%-2682.8%100.0%
Research & Development62.69M60.03M139.14M168.06M
Selling, General & Admin13.51M17.11M29.75M53.32M
Operating Expenses14.51M87.15M29.75M221.39M
Depreciation & Amortization78K113K137K56K
EBITDA(75.12M)(27.03M)(156.42M)(370.43M)
EBITDA Margin—-54.1%-3128.4%-3704.3%
Operating Income(76.2M)(37.15M)(163.89M)(211.39M)
Operating Margin—-74.3%-3277.8%-2113.8%
Interest Income00012.15M
Interest Expense0007.33M
Other Income / Expenses(43.08M)324K7.33M(166.43M)
Income Before Tax(119.28M)(36.82M)(156.56M)(377.82M)
Pre-Tax Margin—-73.6%-3131.2%-3778.2%
Income Tax Expense0301K429K(79K)
Net Income(119.28M)(37.12M)(156.99M)(377.74M)
Net Margin—-74.2%-3139.8%-3777.4%
EPS (Basic)(3.11)(0.97)(3.76)(8.44)
EPS (Diluted)(3.11)(0.97)(3.76)(8.44)
Weighted Avg Shares38.32M38.32M41.79M44.73M
Weighted Avg Shares (Diluted)38.32M38.32M41.79M44.73M

Zenas BioPharma, Inc.

NASDAQ:ZBIO

Intrinsic Alpha fair value

Locked

Current Price

$26.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.